Hoth Therapeutics announces positive preclinical research in Alzheimer’s

Hoth Therapeutics unveiled “positive” pre-clinical research involving HT-ALZ, an Alzheimer’s disease therapeutic. HT-ALZ combats neuroinflammation and cognitive deficits associated with Alzheimer’s Disease. By antagonizing the NK1 receptor, HT-ALZ reduces soluble Abeta levels in the brain’s interstitial fluid and diminishes anxiety-like behavior and enhances cognitive function in preclinical models. The research presents evidence of HT-ALZ’s capacity to improve memory tasks related to the hippocampus and sensorimotor gating. While the effects on plaque deposition and Abeta levels were inconclusive, the treatment’s cognitive benefits suggest that HT-ALZ’s mode of action may involve a reduction in brain inflammation, thereby improving cognitive outcomes for Alzheimer’s patients. Hoth Therapeutics remains committed to further research and development of HT-ALZ, including analyses of its effects on microglial activation and brain inflammation.